Cost-effectiveness of treatment with etanercept for psoriasis in Sweden

Overview of attention for article published in HEPAC Health Economics in Prevention and Care, March 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 1 news outlet

policy: 2 policy sources

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 62 Mendeley

Summary News Policy documents Dimensions citations

So far, Altmetric has seen 5 policy documents that reference this research output.

Secukinumab

Cited by Canadian Agency for Drugs and Technologies in Health on 04 Dec 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Apremilast

Cited by Canadian Agency for Drugs and Technologies in Health on 05 Oct 2018

brodalumab

Cited by Canadian Agency for Drugs and Technologies in Health on 11 Jul 2018

Ixekizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 25 Sep 2017

Ixekizumab for treating moderate to severe plaque psoriasis: Committee papers

Cited by National Institute for Health and Care Excellence on 25 Oct 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.